Takaki M - Search Results

1

Aripiprazole is effective for treatment of delayed sleep phase syndrome.

Takaki M, Ujike H. Takaki M, et al. Clin Neuropharmacol. 2014 Jul-Aug;37(4):123-4. doi: 10.1097/WNF.0000000000000035. Clin Neuropharmacol. 2014. PMID: 24992089

2

[Overview of genetics and substance use disorders].

Takaki M, Okahisa Y, Ujike H. Takaki M, et al. Nihon Rinsho. 2010 Aug;68(8):1451-6. Nihon Rinsho. 2010. PMID: 20715475 Review. Japanese.

3

Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.

Takaki M, Ujike H. Takaki M, et al. Clin Neuropharmacol. 2013 Mar-Apr;36(2):68-9. doi: 10.1097/WNF.0b013e318280028a. Clin Neuropharmacol. 2013. PMID: 23503552

4

Aripiprazole as monotherapy at bedtime was effective for treatment of two cases of obsessive-compulsive disorder and insomnia.

Takaki M. Takaki M. J Neuropsychiatry Clin Neurosci. 2014 Summer;26(3):E64. doi: 10.1176/appi.neuropsych.13100245. J Neuropsychiatry Clin Neurosci. 2014. PMID: 25093799 No abstract available.

5

Aripiprazole may be effective as an add-on treatment in bulimic symptoms of eating disorders.

Takaki M, Okabe N. Takaki M, et al. J Clin Psychopharmacol. 2015 Feb;35(1):93-5. doi: 10.1097/JCP.0000000000000233. J Clin Psychopharmacol. 2015. PMID: 25370125 No abstract available.

6

Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.

Mizuki Y, Takaki M. Mizuki Y, et al. Among authors: takaki m. J Clin Psychopharmacol. 2015 Feb;35(1):101-2. doi: 10.1097/JCP.0000000000000267. J Clin Psychopharmacol. 2015. PMID: 25502488 No abstract available.

7

Effect and tolerability of blonanserin in severe delusion with various types of dementia.

Takaki M, Honda H, Terada S, Uchitomi Y. Takaki M, et al. Psychogeriatrics. 2015 Jun;15(2):144-146. doi: 10.1111/psyg.12090. Epub 2014 Dec 16. Psychogeriatrics. 2015. PMID: 25515063

8

Anti-Inflammatory Therapy and Immunotherapy Were Partially Effective in a Patient With Anti-N-Methyl-D-Aspartate Receptor Antibodies and a Special Subgroup of Treatment-Resistant Schizophrenia.

Senda M, Bessho K, Oshima E, Sakamoto S, Tanaka K, Tsutsui K, Kanbayashi T, Takaki M, Yoshimura B. Senda M, et al. Among authors: takaki m. J Clin Psychopharmacol. 2016 Feb;36(1):92-3. doi: 10.1097/JCP.0000000000000439. J Clin Psychopharmacol. 2016. PMID: 26658265 No abstract available.

9

Encephalitis With Antibodies to GluN2B During Administration of Clozapine.

Gon J, Takehisa Y, Yada Y, Kishi Y, Oshima E, Takahashi Y, Takaki M. Gon J, et al. Among authors: takaki m. Clin Neuropharmacol. 2016 Nov/Dec;39(6):320-321. doi: 10.1097/WNF.0000000000000181. Clin Neuropharmacol. 2016. PMID: 27482955

10

The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study.

Yoshimura B, Yada Y, So R, Takaki M, Yamada N. Yoshimura B, et al. Among authors: takaki m. Psychiatry Res. 2017 Apr;250:65-70. doi: 10.1016/j.psychres.2017.01.064. Epub 2017 Jan 24. Psychiatry Res. 2017. PMID: 28142068

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results